A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 298 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR FDA Approves Mirvetuximab Soravtansine-gynx for FRα-positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube,... April 9, 2024 EMA Recommends Extension of Indications for Daratumumab June 10, 2021 A Combination of Oral Mezigdomide Plus Dexamethasone Shows Promising Efficacy in... September 28, 2023 New Approach May Help People with Cancer Better Manage Depression, Pain,... May 14, 2024 Load more HOT NEWS From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors’ Wellbeing,... Could food improve cancer treatment? – That Cancer Conversation Surgery for Recurrent Ovarian Cancer Does Not Improve Survival How to Avoid Spreading Harmful Chemo Chemicals to Members of Your...
